Amy J. Reed, MD, died 4 years following her surgery that used a power morcellator to remove her uterus, resulting in the spread of a hidden cancer.
She developed stage 4 leiomyosarcoma following a routine hysterectomy that was meant to take care of her fibroids. Amy J. Reed, MD, has died, 4 years following her surgery that used a power morcellator to remove her uterus.
The reason: use of a power morcellator that slices the tissue into small pieces that can then be extracted through minimally invasive surgery, which allows for faster recovery. However, what went unnoticed was that if a patient has cancer, the power morcellator accelerates the spread of cancer—this happened with Reed.
Reed’s surgery was conducted at Brigham and Women’s Hospital in Boston, within the Harvard Medical School, where she and her husband, Hooman Noorchashm, MD, hold teaching positions. A biopsy post surgery was the first diagnosis of Reed’s cancer—the morcellator had sprayed her malignant cells around her abdomen. Despite aggressive chemotherapy, radiation therapy, and immunotherapy, she suffered multiple recurrences in her abdomen, lungs, and spine.
The couple then took their case to regulatory authorities, as well as device makers, hospitals, and multiple other organizations, to raise awareness around the danger of the power morcellator. They also enlisted other women who had undergone the procedure, or their families, to join the campaign. The primary result of their effort was a study conducted and publicized by the FDA that found hidden sarcomas were more common than was previously thought—the number was 1 in 350, not 1 in 10,000. As an immediate effect, Johnson & Johnson, one of the companies that manufactured the device, suspended sales of its product.
Subsequently, the FDA banned the use of power morcellators for the removal of the uterus or fibroids in a majority of women. Additionally, the FDA asked manufacturers of these devices to include specific safety statements as black box warnings on the product label.
Aetna was the first health plan to take a stand in reaction to the FDA decision. In the summer of 2015, the company announced it would not cover use of power morcellators for myomectomy and hysterectomy procedures in most cases and that doctors would require a precertification if they do need to use the device for said procedures. UnitedHealth requires physicians to obtain prior authorization from the insurance company before using the device for hysterectomy.
Reed leaves behind her husband and 6 children.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Uniting to Support Patients With Cancer Beyond Treatment
November 17th 2024Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center of all strategic partnerships between academic institutions and community-based oncology practices.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Bridging Cancer Care Gaps and Overcoming Medical Mistrust
November 13th 2024In this clip from our interview with Oscar B. Lahoud, MD, cochair of our Institute for Value-Based Medicine® evening hosted with NYU Langone Health, he addressed medical mistrust in underrepresented communities.
Read More
How English- and Spanish-Preferring Patients With Cancer Decide on Emergency Care
November 13th 2024Care delivery innovations to help patients with cancer avoid emergency department visits are underused. The authors interviewed English- and Spanish-preferring patients at 2 diverse health systems to understand why.
Read More